BSI-201, targets PARP, or poly (ADP-ribose) polymerase, a key enzyme involved in DNA repair and cell proliferation. By inhibiting the enzymatic activity of PARP, BSI-201 significantly enhances the anti-tumor effects of chemotherapy and has shown promising safety and efficacy results in patients with solid tumors.
BSI-201 is in Phase 2 clinical studies of patients with triple negative breast cancer, ovarian cancer and other malignancies.
